CEL SCI CORP
CVMCel-Sci Corporation (NYSE American: CVM), is a biotechnology company that tests drugs for the treatment of cancer, autoimmune and infectious diseases through the research and development of immunotherapy products.
Drugs in Pipeline
1
Phase 3 Programs
1
Upcoming Catalysts
1
Next Catalyst
Aug 13, 2026
9dMarket Overview
Stock performance and key metrics
1 upcoming, 0 past
CVM Earnings Report
FQ end 2026-06
How CVM's past catalysts played out
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
LI | Phase 3 | Squamous Cell Carcinoma of the Oral Cavity | - | - |
Full breakdown — the signals behind the verdict
Frequently asked questions
What is in CEL SCI CORP's drug pipeline?→
CatalystAlert tracks 1 drug candidate in CEL SCI CORP's (CVM) pipeline across Phase 3. Its lead program is LI (Phase 3). Each drug's phase, indication and upcoming catalysts are listed on this page.
When is CEL SCI CORP's next FDA catalyst?→
CEL SCI CORP's (CVM) next tracked catalyst is a Earnings expected August 13, 2026. See the catalyst timeline on this page for the full schedule of PDUFA dates, trial readouts and FDA events.
How do I track CVM biotech catalysts?→
Add CVM to your CatalystAlert watchlist for alerts ahead of each catalyst, and follow CEL SCI CORP's live catalyst calendar, drug pipeline and clinical-trial timeline on this page — sourced from ClinicalTrials.gov, FDA and SEC filings.